title: Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.
abstract: CK2 is a master regulator protein kinase which demonstrates heightened expression in diverse cancer types and is considered a promising target for therapy. Given its ubiquitous expression and potent influence on cell survival, cancer cell-directed targeting of the CK2 signal is an important factor for development of an anti-CK2 therapeutic. We previously reported on the malignant cell specificity and effect on CK2 signaling of a tenfibgen (TBG) based nanocapsule for delivery of the CK2 small molecule inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) in cultured prostate cancer cells. Here we tested the ability of TBG-DMAT to affect the growth of prostate xenograft tumors in mice. Our results show that treatment of PC3-LN4 xenograft tumors with TBG-DMAT caused loss of proliferative Ki-67 signal as well as Nuclear Factor-kappa B (NF-κB) expression in the tumors. Further, the TBG-DMAT nanocapsule was detected in tumors and not in liver or testis. In conclusion, TBG-based nanocapsule delivery of anti-CK2 small molecule drugs holds significant promise for treatment of prostate cancer.
authors.affiliation: Research Service, Minneapolis VA Health Care System, Minneapolis ; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis ; Masonic Cancer Center, University of Minnesota, Minneapolis.
authors.forename: Janeen H
authors.initials: JH
authors.lastname: Trembley
authors.affiliation: GeneSegues Inc., Chaska, Minnesota.
authors.forename: Gretchen M
authors.initials: GM
authors.lastname: Unger
authors.affiliation: Research Service, Minneapolis VA Health Care System, Minneapolis ; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.
authors.forename: Omar Cespedes
authors.initials: OC
authors.lastname: Gomez
authors.affiliation: Research Service, Minneapolis VA Health Care System, Minneapolis ; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.
authors.forename: J
authors.initials: J
authors.lastname: Abedin
authors.affiliation: GeneSegues Inc., Chaska, Minnesota.
authors.forename: Vicci L
authors.initials: VL
authors.lastname: Korman
authors.affiliation: Masonic Cancer Center, University of Minnesota, Minneapolis.
authors.forename: Rachel I
authors.initials: RI
authors.lastname: Vogel
authors.affiliation: Pathology and Laboratory Medicine Service, Minneapolis VA Health Care System, Minneapolis.
authors.forename: Gloria
authors.initials: G
authors.lastname: Niehans
authors.affiliation: Research Service, Minneapolis VA Health Care System, Minneapolis ; Masonic Cancer Center, University of Minnesota, Minneapolis.
authors.forename: Betsy T
authors.initials: BT
authors.lastname: Kren
authors.affiliation: Research Service, Minneapolis VA Health Care System, Minneapolis ; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis ; Department of Urology, University of Minnesota, Minneapolis ; Masonic Cancer Center, University of Minnesota, Minneapolis.
authors.forename: Khalil
authors.initials: K
authors.lastname: Ahmed
keywords: CK2; DMAT; Nanocapsule; Nanoparticle; Prostate Cancer; Tenfibgen